Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atreleuton. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 known ✓ | P09917 | 18/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 7/20 | 1.00 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atreleuton SCHEMBL2108309 | 1.00 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| Atreleuton SCHEMBL2107799 | 1.00 | ALOX5 (1.00) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL13140100 | 0.91 | ALOX5 (0.83) | ALOX5EPHX2 | |
| SCHEMBL8309861 | 0.90 | ALOX5 (0.82) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8305234 | 0.90 | ALOX5 (0.82) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL2109641 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL2109638 | 0.89 | ALOX5 (0.80) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8303838 | 0.88 | ALOX5 (0.79) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8303836 | 0.88 | ALOX5 (0.79) | ALOX5EPHX2ACACBACACA | |
| SCHEMBL8948277 | 0.88 | ALOX5 (0.78) | ALOX5EPHX2ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014031586-A2 | METHODS FOR TREATING CARDIOVASCULAR DISEASES | TALLIKUT PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20130317078-A1 | PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES | TALLIKUT PHARMACEUTICALS INC (US) | 2013-11-28 | — | — | US | claimed |
| US-20130190514-A1 | PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES | TALLIKUT PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | claimed |
| EP-2598141-A2 | PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES | Tallikut Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | claimed |
| WO-2012015750-A2 | PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | claimed |
| US-20120029048-A1 | PHENYLALKYL N-HYDROXYUREAS FOR TREATING LEUKOTRIENE RELATED PATHOLOGIES | VIA PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | claimed |
| US-7495024-B2 | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque | VIA PHARMACEUTICALS, INC. (US) | 2009-02-24 | — | — | US | claimed |
| US-20080033034-A1 | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque | MADRIGAL PHARMACEUTICALS, INC. | 2008-02-07 | — | — | US | claimed |
| US-7132441-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. (US) | 2006-11-07 | — | — | US | claimed |
| CN-1655846-A | Combination of a PDE inhibitor and a leukotriene receptor antagonist | ALTANA PHARMA AG (DE) | 2005-08-17 | — | — | CN | claimed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| EP-0667855-B1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 1999-03-24 | — | — | EP | claimed |
| WO-1998058645-A1 | (S)-(-)-N-[3- [5-[(4-FLUOROPHENYL)METHYL] -2-THIENYL]-1-METHYL -2-PROPYNYL]-N-HYDROXYUREA | SEPRACOR, INC. (US) | 1998-12-30 | — | — | WO | claimed |
| EP-0804157-A1 | AEROSOL DRUG FORMULATIONS CONTAINING VITAMIN E | Abbott Laboratories (US) | 1997-11-05 | — | — | EP | claimed |
| US-5635161-A | PULMONARY DELIVERY | ABBOTT LABORATORIES (US) | 1997-06-03 | — | — | US | claimed |
| EP-0667855-A4 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS. | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | claimed |
| WO-1995024892-A1 | AEROSOL DRUG FORMULATIONS CONTAINING VITAMIN E | ABBOTT LABORATORIES (US) | 1995-09-21 | — | — | WO | claimed |
| EP-0667855-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1995-08-23 | — | — | EP | claimed |
| WO-1994011342-A1 | SUBSTITUTED ARYLALKYNYL- AND HETEROARYLALKYNYL-N-HYDROXYUREA INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-05-26 | — | — | WO | claimed |
| US-5288751-A | [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033034-A1 | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque | APOB, HHAT, LIPA | ALOX5 912/4885EPHX2 1213/4885ACACB 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.